Heron Therapeutics (HRTX) Common Equity (2010 - 2026)

Heron Therapeutics has reported Common Equity for 17 years, with the latest figure at $9.1 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 132.11% year-over-year to $9.1 million; the trailing twelve-month figure through Mar 2026 stood at $9.1 million (up 132.11% YoY), and the FY2025 full-year result was $14.3 million, up 142.59% from the prior year.
• Common Equity for Q1 2026 stood at $9.1 million, down from $14.3 million in the prior quarter.
• The five-year high for Common Equity was $24.0 million in Q1 2022, with the low at -$40.0 million in Q3 2024.
• Historically, Common Equity has averaged -$13.9 million across 5 years, with a median of -$27.3 million in 2025.
• Annual changes were most pronounced in 2023 — Common Equity tumbled 350.32% — and 2025, when it jumped 142.59%.
• Heron Therapeutics' Common Equity stood at $13.6 million in 2022, then sank by 350.32% to -$34.0 million in 2023, then increased by 0.95% to -$33.7 million in 2024, then soared by 142.59% to $14.3 million in 2025, then tumbled by 36.25% to $9.1 million in 2026.
• The last three Common Equity figures came in at $9.1 million (Q1 2026), $14.3 million (Q4 2025), and $14.9 million (Q3 2025), per Business Quant data.